Cytek Biosciences (CTKB) EBIAT (2020 - 2025)
Cytek Biosciences' EBIAT history spans 6 years, with the latest figure at -$44.1 million for Q4 2025.
- For Q4 2025, EBIAT fell 557.08% year-over-year to -$44.1 million; the TTM value through Dec 2025 reached -$66.5 million, down 1005.48%, while the annual FY2025 figure was -$66.5 million, 1005.3% down from the prior year.
- EBIAT reached -$44.1 million in Q4 2025 per CTKB's latest filing, down from -$5.5 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $9.6 million in Q4 2024 to a low of -$44.1 million in Q4 2025.
- Average EBIAT over 5 years is -$4.0 million, with a median of -$1.7 million recorded in 2021.
- The largest YoY upside for EBIAT was 419.14% in 2022 against a maximum downside of 2215.69% in 2022.
- A 5-year view of EBIAT shows it stood at -$1.2 million in 2021, then soared by 419.14% to $3.7 million in 2022, then skyrocketed by 48.01% to $5.5 million in 2023, then soared by 75.23% to $9.6 million in 2024, then plummeted by 557.08% to -$44.1 million in 2025.
- Per Business Quant, the three most recent readings for CTKB's EBIAT are -$44.1 million (Q4 2025), -$5.5 million (Q3 2025), and -$5.6 million (Q2 2025).